


# Causality assessment of an adverse event following immunization (AEFI)

User manual for the revised  
WHO classification



Second edition  
2019 update



# **Causality assessment of an adverse event following immunization (AEFI)**

User manual for the revised  
WHO classification

Second edition  
2019 update

Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification second edition, 2019 update

ISBN 978-92-4-151699-0 (electronic version)

ISBN 978-92-4-000924-0 (print version)

**© World Health Organization 2019**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification second edition, 2019 update. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout: Agence Gardeners (Annecy, France)

# Contents

Purpose .....	vi
Acknowledgements.....	vii
The 2019 update and what is new .....	viii
Glossary .....	ix
Acronyms.....	xi

## I. INTRODUCTION AND RATIONALE

Adverse events following immunization – Key definitions .....	2
General definition.....	2
Cause-specific definitions.....	2

## II. KEY CONSIDERATIONS FOR CAUSALITY ASSESSMENT OF AEFI

AEFI causality assessment in practice.....	5
--	---

## III. LEVELS OF CAUSALITY ASSESSMENT AND THEIR SCIENTIFIC BASIS

1. The population level.....	9
2. The individual level .....	10
3. Investigation of signals .....	11

## IV. CASE SELECTION FOR CAUSALITY ASSESSMENT OF AEFI

Prerequisites for causality assessment.....	15
Who should do causality assessment?.....	16

## V. STEPS FOR CAUSALITY ASSESSMENT OF AN INDIVIDUAL ADVERSE EVENT FOLLOWING IMMUNIZATION

Step 1: Eligibility .....	20
Step 2: Checklist.....	22
I. Is there strong evidence for other causes?.....	24
II. Is there a known causal association with the vaccine or vaccination?..	25
II (time): Was the event in section II within the time window of increased risk (i.e. ‘Yes’ response to questions from II 1 to II 11 above)?.....	31
III. Is there strong evidence against a causal association?.....	32
IV. Other qualifying factors for classification .....	32
Step 3: Algorithm.....	35
Step 4: Classification .....	37
I. Case with adequate information for causality conclusion .....	38
II. Case without adequate information for causality conclusion.....	38

## VI. SUMMARIZING THE LOGIC OF AEFI CAUSALITY ASSESSMENT .....

VI. SUMMARIZING THE LOGIC OF AEFI CAUSALITY ASSESSMENT .....	40
<b>VII. UNDERLYING MECHANISMS FOR THE CLASSIFICATION OF ADVERSE EVENTS FOLLOWING IMMUNIZATION</b>	
A. Consistent causal association to immunization.....	45
A1 and A2. Vaccine product-related and vaccine quality defect-related reactions.....	45
A3. Immunization error-related reaction.....	47
A4. Immunization anxiety-related reaction (Immunization stress related responses - ISRR) .....	48
B. Indeterminate.....	49
B1. Consistent temporal relationship but insufficient evidence for causality.....	49
B2. Conflicting trends of consistency and inconsistency with causality ...	49

C. Inconsistent causal association to immunization (coincidental).....	50
Underlying or emerging condition(s) in the vaccine.....	50
Conditions caused by exposure to external factors .....	50
<b>VIII. INITIATING ACTION AFTER CAUSALITY ASSESSMENT OF AN AEFI</b>	
A. Consistent causal association to immunization.....	53
A1. Vaccine product-related reaction .....	53
A2. Vaccine quality defect-related reaction .....	53
A3. Immunization error-related reaction.....	54
A4. Immunization anxiety-related reaction (Immunization stress related response - ISRR) .....	54
B. Indeterminate.....	54
B1. Consistent temporal relationship but insufficient evidence for causality.....	54
B2. Conflicting trends of consistency and inconsistency with causality ...	54
C. Inconsistent causal association to immunization (coincidental).....	55
D. Ineligible cases and Unclassifiable cases .....	55
<b>IX. CONCLUSION .....</b>	56
<b>ANNEXES.....</b>	58
<b>Example 1: Meningococcal conjugate vaccine and seizures .....</b>	61
<b>Example 2: OPV and acute flaccid paralysis .....</b>	64
<b>Example 3: AEFI after MMR vaccine .....</b>	67

## Purpose

This user manual serves as a guide to a systematic, standardized global causality assessment process for individual serious adverse events following immunization (AEFI). It is intended to be used by staff

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23963](https://www.yunbaogao.cn/report/index/report?reportId=5_23963)

